Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 March 2018 Photo Earl Coetzee
Research focus on HIV and TB stigma among healthcare workers
Posters reading, “Let’s Stop Stigma” urge healthcare workers to ”Be kind to yourself. Be kind to others.” Pictured here are Dr Asta Rau, Director of CHSR&D and Dr Michelle Engelbrecht, deputy director of the centre.

Researchers working on an internationally funded project are tackling a key occupational health issue: HIV and TB stigma among Free State healthcare workers. They developed and rolled out interventions to decrease stigma and will soon measure the effects. 
In this four-year project, UFS researchers from the Centre for Health Systems Research and Development (CHSR&D) are partnering with Antwerp University and the Free State Department of Health.  

Stigma is like an invisible mark 
A project leader at the CHSR&D, Dr Asta Rau, says most research on stigma in public health focuses on HIV stigma towards patients. Little is done on stigma among healthcare workers themselves. 
Dr Rau says that stigma undermines people’s dignity and causes them suffering. It can even stop them from seeking healthcare. Stigma threatens the health of healthcare workers and the stability of the health system, which is already under strain due to personnel shortages. 

Interventions to make a difference

The research identified two types of stigma - external stigma that can be seen around us, e.g. in the way healthcare workers speak about or treat one another and internal stigma that happens when healthcare workers take this ‘outside’ stigma and turn it inward on themselves. 

Dr Rau says the interventions involve training healthcare workers about what stigma is and how to go about reducing it. “We give them the knowledge and tips on how to communicate when they encounter stigma. It is up to them to then use that to fight stigma.” A communication campaign with posters and branded social marketing materials supports the training. The campaign uses a single slogan: ”Let’s Stop Stigma” and urges healthcare workers to ”Be kind to yourself. Be kind to others."

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept